======= BEND3 ======= == Gene Information == * **Official Symbol**: BEND3 * **Official Name**: BEN domain containing 3 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=57673|57673]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q5T5X7|Q5T5X7]] * **Interactions**: [[https://thebiogrid.org/search.php?search=BEND3&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20BEND3|Open PubMed]] * **OMIM**: [[https://omim.org/entry/616374|Open OMIM]] == Function Summary == * **Entrez Summary**: N/A * **UniProt Summary**: Transcriptional repressor which associates with the NoRC (nucleolar remodeling complex) complex and plays a key role in repressing rDNA transcription. The sumoylated form modulates the stability of the NoRC complex component BAZ2A/TIP5 by controlling its USP21-mediated deubiquitination (PubMed:21914818, PubMed:26100909). Binds to unmethylated major satellite DNA and is involved in the recruitment of the Polycomb repressive complex 2 (PRC2) to major satellites (By similarity). Stimulates the ERCC6L translocase and ATPase activities (PubMed:28977671). {ECO:0000250|UniProtKB:Q6PAL0, ECO:0000269|PubMed:21914818, ECO:0000269|PubMed:26100909, ECO:0000269|PubMed:28977671}. |BEN| |histone H3-K9 trimethylation| |rDNA binding| |histone H4-K20 trimethylation| |histone H3-K27 trimethylation| |histone H4-K20 methylation| |histone H3-K27 methylation| |chromatin silencing at rDNA| |histone H3-K9 methylation| |histone H3-K4 trimethylation| |histone H3-K9 modification| |nuclear heterochromatin| |peptidyl-lysine trimethylation| |histone H3-K4 methylation| |positive regulation of ATP metabolic process| |DNA alkylation| |DNA methylation| |histone H4 acetylation| |chromatin organization involved in negative regulation of transcription| |chromatin silencing| |DNA methylation or demethylation| |chromatin organization involved in regulation of transcription| |histone lysine methylation| |negative regulation of gene expression, epigenetic| |peptidyl-lysine methylation| |DNA modification| |histone methylation| |histone acetylation| |internal peptidyl-lysine acetylation| |regulation of ATP metabolic process| |peptidyl-lysine acetylation| |internal protein amino acid acetylation| |protein alkylation| |protein methylation| |protein acetylation| |gene silencing| |protein acylation| |regulation of gene expression, epigenetic| |macromolecule methylation| |methylation| |peptidyl-lysine modification| |protein homooligomerization| |histone modification| |covalent chromatin modification| |protein complex oligomerization| |chromatin organization| |DNA metabolic process| |nucleolus| |negative regulation of transcription by RNA polymerase II| |peptidyl-amino acid modification| |chromosome organization| |negative regulation of transcription, DNA-templated| |negative regulation of nucleic acid-templated transcription| |negative regulation of RNA biosynthetic process| |negative regulation of RNA metabolic process| |negative regulation of cellular macromolecule biosynthetic process| |negative regulation of nucleobase-containing compound metabolic process| |negative regulation of macromolecule biosynthetic process| |negative regulation of cellular biosynthetic process| |negative regulation of biosynthetic process| |protein-containing complex assembly| |negative regulation of gene expression| |protein-containing complex subunit organization| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp527|Tanespimycin 14μM R08 exp527]]|1.77| |[[:results:exp355|Dinaciclib 0.007μM R07 exp355]]|1.78| |[[:results:exp106|UM131593 0.2μM R03 exp106]]|1.86| |[[:results:exp533|TNF-alpha 44ng/ml R08 exp533]]|2.02| |[[:results:exp534|Trientine 500μM R08 exp534]]|2.21| |[[:results:exp365|I-BRD9 4μM R07 exp365]]|2.23| |[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|2.34| |[[:results:exp282|Fluvastatin 2.2μM R06 exp282]]|2.36| |[[:results:exp28|Pimelic-diphenylamide-106 5μM R00 exp28]]|2.64| |[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|2.76| |[[:results:exp447|Amiloride 100μM R08 exp447]]|3| |[[:results:exp409|THZ531 0.11μM R07 exp409]]|3.47| |[[:results:exp410|THZ531 0.11 to 0.125μM on day4 R07 exp410]]|4.14| |[[:results:exp102|Nifuroxazide 5μM R03 exp102]]|4.31| |[[:results:exp413|THZ531 0.11 to 0.175μM on day4 R07 exp413]]|6.37| |[[:results:exp505|ML-792 0.2μM R08 exp505]]|6.42| |[[:results:exp531|THZ1 0.06μM R08 exp531]]|7.22| |[[:results:exp412|THZ531 0.11 to 0.125 to 0.35μM on day4 then day6 R07 exp412]]|7.43| |[[:results:exp444|THZ531 0.225μM R08 exp444]]|8.1| |[[:results:exp21|MLN-4924 0.2μM R00 exp21]]|8.48| No correlation found to any other genes in chemogenomics. Global Fraction of Cell Lines Where Essential: 1/739 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/28| |bone|0/26| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/16| |kidney|1/21| |liver|0/20| |lung|0/75| |lymphocyte|0/16| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/9| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 3042 * **Expression level (log2 read counts)**: 5.46 {{:chemogenomics:nalm6 dist.png?nolink |}}